3 Undervalued Pharmaceuticals Stocks for Monday, March 25
Discover the top 3 undervalued Pharmaceuticals stocks for Monday, March 25 based on AAII’s Stock Grades.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Jenna Brashear
| Share Statistics | AKAN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $11.2 | $421.5 | 9% |
|
| Shares Out (Mil) | 0.5 | 46.9 | 3% |
|
| Institutional Ownership | 56.2% | 82.0% | 37% |
|
| Float (Mil) | 2.4 | 49.2 | 7% |
|
| Beta | na | 0.68 | na |
|
| Avg Daily Volume (000s) | 37,850 | 347 | 99% |
|
| Price Change (52-week) |
(79.6%) | 49.3% | 10% |
|
| Growth | AKAN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.4% | na |
|
| Net Income (5yr) | (81.8%) | (1.3%) | 3% |
|
| EPS (5yr) | na | 15.1% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | AKAN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $275 | 1% |
|
| Net Income (TTM) (Mil) | ($51) | ($11) | 16% |
|
| EPS (TTM) | ($161.483) | ($0.700) | 1% |
|
| Operating Cash Flow (TTM) (Mil) | ($10) | ($7) | 21% |
|
| Net Cash Flow (TTM) (Mil) | ($2) | $1 | 40% |
|
| Long-Term Debt (Q1) (Mil) | $10 | $6 | 28% |
|
| Enterprise Value (Q1) (Mil) | $18 | $331 | 12% |
|
| Valuation | AKAN | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.08 | na |
|
| P/E | na | 20.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | AKAN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (12.0%) | 69.5% | 3% |
|
| Net Margin | na | 3.6% | na |
|
| ROA | (806.9%) | (23.8%) | 0% |
|
| ROE | 856.6% | (24.2%) | 100% |
|
| Liabilities to Assets | 356.0% | 31.6% | 100% |
|
| F-Score | 1 | 3 | 1% |
|
Akanda Corp. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors